SaBrcada: Survival Intervals Prediction for Breast Cancer Patients by Dimension Raising and Age Stratification

Author:

Lin Shih-Huan1,Chien Ching-Hsuan1,Chang Kai-Po2ORCID,Lu Min-Fang3,Chen Yu-Ting1345,Chu Yen-Wei134567ORCID

Affiliation:

1. Ph.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 40227, Taiwan

2. Department of Pathology, China Medical University Hospital, Taichung 404327, Taiwan

3. Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 40227, Taiwan

4. Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan

5. Agricultural Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan

6. Institute of Molecular Biology, National Chung Hsing University, Taichung 40227, Taiwan

7. Smart Sustainable New Agriculture Research Center (SMARTer), Taichung 40227, Taiwan

Abstract

(1) Background: Breast cancer is the second leading cause of cancer death among women. The accurate prediction of survival intervals will help physicians make informed decisions about treatment strategies or the use of palliative care. (2) Methods: Gene expression is predictive and correlates to patient prognosis. To establish a reliable prediction tool, we collected a total of 1187 RNA-seq data points from breast cancer patients (median age 58 years) in Fragments Per Kilobase Million (FPKM) format from the TCGA database. Among them, we selected 144 patients with date of death information to establish the SaBrcada-AD dataset. We first normalized the SaBrcada-AD dataset to TPM to build the survival prediction model SaBrcada. After normalization and dimension raising, we used the differential gene expression data to test eight different deep learning architectures. Considering the effect of age on prognosis, we also performed a stratified random sampling test on all ages between the lower and upper quartiles of patient age, 48 and 69 years; (3) Results: Stratifying by age 61, the performance of SaBrcada built by GoogLeNet was improved to a highest accuracy of 0.798. We also built a free website tool to provide five predicted survival periods: within six months, six months to one year, one to three years, three to five years, or over five years, for clinician reference. (4) Conclusions: We built the prediction model, SaBrcada, and the website tool of the same name for breast cancer survival analysis. Through these models and tools, clinicians will be provided with survival interval information as a basis for formulating precision medicine.

Funder

National Science and Technology Council, Taiwan

Smart Sustainable New Agriculture Research Center

China Medical University Hospital

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference43 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3